Golledge J, Powell J T
Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia 4811.
Eur J Vasc Endovasc Surg. 2007 Sep;34(3):267-73. doi: 10.1016/j.ejvs.2007.03.006. Epub 2007 May 30.
Medical management of patients with abdominal aortic aneurysm (AAA) is required for several different reasons. Since these patients have an increased risk of cardiovascular death therapy to reduce cardiovascular events is essential. Treatment is in line with the medical management of coronary artery disease including smoking cessation, statins and anti-platelet therapy. Some of these therapies also will slow aneurysm growth. Currently there is no proven focused therapy that reduces aneurysm growth, but the emerging strategies are discussed. Medical management also is required to reduce peri-operative risks and stabilise endovascular aneurysm repair. Whilst some of the therapies targeting cardiovascular risk reduction may be helpful, other emerging strategies are discussed.
出于多种不同原因，需要对腹主动脉瘤（AAA）患者进行医学管理。由于这些患者心血管死亡风险增加，因此减少心血管事件的治疗至关重要。治疗与冠状动脉疾病的医学管理一致，包括戒烟、使用他汀类药物和抗血小板治疗。其中一些治疗方法也会减缓动脉瘤的生长。目前尚无经证实的可减少动脉瘤生长的针对性治疗方法，但对新兴策略进行了讨论。还需要进行医学管理以降低围手术期风险并稳定血管内动脉瘤修复。虽然一些旨在降低心血管风险的治疗方法可能会有所帮助，但也对其他新兴策略进行了讨论。
